GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Aeterna Zentaris, Inc. (AEZS) [hlAlert]

Rating:
Buy AEZS
down 97.97 %

Aeterna Zentaris, Inc. (AEZS) rated Buy by ROTH Capital

Posted on: Thursday,  Sep 20, 2012  8:25 AM ET by Roth Capital

Roth Capital rated Buy Aeterna Zentaris, Inc. (NASDAQ: AEZS) on 09/20/2012, when the stock price was $4.44. Since
then, Aeterna Zentaris, Inc. has lost 97.97% as of 12/02/2015's recent price of $0.09.
If you would have followed this Roth Capital's recommendation on AEZS, you would have lost 97.97% of your investment in 1168 days.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology. The product pipeline of the Company encompasses compounds at all stages of development, from drug discovery through marketed products. The Company’s principal product candidates include cetrorelix for benign prostatic hyperplasia (BPH) and AEZS-108 for endometrial and ovarian cancers. In January 2007, the Company completed the spin-off of Atrium Biotechnologies Inc., known as Atrium Innovations (Atrium). On November 30, 2007, the Company completed the sale of its Utah-based subsidiary, Echelon Biosciences Inc. (Echelon), to Frontier Scientific Inc.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/20/2012 8:25 AM Buy
None
4.44
as of 12/31/2012
1 Week up  9.67 %
1 Month up  4.84 %
3 Months down  -43.33 %
1 YTD down  -46.39 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy